270 related articles for article (PubMed ID: 36049604)
21. Efficacy of Intravenous Ketamine in Adolescent Treatment-Resistant Depression: A Randomized Midazolam-Controlled Trial.
Dwyer JB; Landeros-Weisenberger A; Johnson JA; Londono Tobon A; Flores JM; Nasir M; Couloures K; Sanacora G; Bloch MH
Am J Psychiatry; 2021 Apr; 178(4):352-362. PubMed ID: 33653121
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study.
Popova V; Daly EJ; Trivedi M; Cooper K; Lane R; Lim P; Mazzucco C; Hough D; Thase ME; Shelton RC; Molero P; Vieta E; Bajbouj M; Manji H; Drevets WC; Singh JB
Am J Psychiatry; 2019 Jun; 176(6):428-438. PubMed ID: 31109201
[TBL] [Abstract][Full Text] [Related]
23. Biomarkers of ketamine's antidepressant effect: An umbrella review.
Meshkat S; Ho RC; Cao B; Teopiz KM; Rosenblat JD; Rhee TG; Di Vincenzo JD; Ceban F; Jawad MY; McIntyre RS
J Affect Disord; 2023 Feb; 323():598-606. PubMed ID: 36521662
[TBL] [Abstract][Full Text] [Related]
24. Ketamine: Future Treatment For Unresponsive Depression?
Frere M; Tepper J
Ir Med J; 2016 Sep; 109(8):453. PubMed ID: 28124853
[TBL] [Abstract][Full Text] [Related]
25. Arketamine, a new rapid-acting antidepressant: A historical review and future directions.
Zhang JC; Yao W; Hashimoto K
Neuropharmacology; 2022 Nov; 218():109219. PubMed ID: 35977629
[TBL] [Abstract][Full Text] [Related]
26. Comparative efficacy, tolerability and acceptability of intravenous racemic ketamine with intranasal esketamine, aripiprazole and lithium as augmentative treatments for treatment-resistant unipolar depression: A systematic review and network meta-analysis.
Terao I; Tsuge T; Endo K; Kodama W
J Affect Disord; 2024 Feb; 346():49-56. PubMed ID: 37949235
[TBL] [Abstract][Full Text] [Related]
27. [Ketamine's antidepressant effect: literature review on clinical use].
De Maricourt P; Jay T; Goncalvès P; Lôo H; Gaillard R
Encephale; 2014 Feb; 40(1):15-23. PubMed ID: 24434008
[TBL] [Abstract][Full Text] [Related]
28. [Pharmacology of ketamine and esketamine as rapid-acting antidepressants].
Pavlidi P; Megalokonomou A; Sofron A; Kokras N; Dalla C
Psychiatriki; 2021 Dec; 32(Supplement I):55-63. PubMed ID: 34990380
[TBL] [Abstract][Full Text] [Related]
29. Ketamine for depression.
Jelen LA; Stone JM
Int Rev Psychiatry; 2021 May; 33(3):207-228. PubMed ID: 33569971
[TBL] [Abstract][Full Text] [Related]
30. A review of ketamine in affective disorders: current evidence of clinical efficacy, limitations of use and pre-clinical evidence on proposed mechanisms of action.
Naughton M; Clarke G; O'Leary OF; Cryan JF; Dinan TG
J Affect Disord; 2014 Mar; 156():24-35. PubMed ID: 24388038
[TBL] [Abstract][Full Text] [Related]
31. The Glutamatergic System in Treatment-Resistant Depression and Comparative Effectiveness of Ketamine and Esketamine: Role of Inflammation?
Halaris A; Cook J
Adv Exp Med Biol; 2023; 1411():487-512. PubMed ID: 36949323
[TBL] [Abstract][Full Text] [Related]
32. The effectiveness, safety and tolerability of ketamine for depression in adolescents and older adults: A systematic review.
Di Vincenzo JD; Siegel A; Lipsitz O; Ho R; Teopiz KM; Ng J; Lui LMW; Lin K; Cao B; Rodrigues NB; Gill H; McIntyre RS; Rosenblat JD
J Psychiatr Res; 2021 May; 137():232-241. PubMed ID: 33706168
[TBL] [Abstract][Full Text] [Related]
33. Esketamine: A Novel Option for Treatment-Resistant Depression.
Bozymski KM; Crouse EL; Titus-Lay EN; Ott CA; Nofziger JL; Kirkwood CK
Ann Pharmacother; 2020 Jun; 54(6):567-576. PubMed ID: 31795735
[No Abstract] [Full Text] [Related]
34. Antidepressant Effect of Ketamine on Inflammation-Mediated Cytokine Dysregulation in Adults with Treatment-Resistant Depression: Rapid Systematic Review.
Sukhram SD; Yilmaz G; Gu J
Oxid Med Cell Longev; 2022; 2022():1061274. PubMed ID: 36160713
[TBL] [Abstract][Full Text] [Related]
35. Intranasal esketamine: A novel drug for treatment-resistant depression.
Khorassani F; Talreja O
Am J Health Syst Pharm; 2020 Aug; 77(17):1382-1388. PubMed ID: 32729898
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and Safety of Fixed-Dose Esketamine Nasal Spray Combined With a New Oral Antidepressant in Treatment-Resistant Depression: Results of a Randomized, Double-Blind, Active-Controlled Study (TRANSFORM-1).
Fedgchin M; Trivedi M; Daly EJ; Melkote R; Lane R; Lim P; Vitagliano D; Blier P; Fava M; Liebowitz M; Ravindran A; Gaillard R; Ameele HVD; Preskorn S; Manji H; Hough D; Drevets WC; Singh JB
Int J Neuropsychopharmacol; 2019 Oct; 22(10):616-630. PubMed ID: 31290965
[TBL] [Abstract][Full Text] [Related]
37. Clinical predictors of depressive symptom remission and response after racemic ketamine and esketamine infusion in treatment-resistant depression.
Jesus-Nunes AP; Leal GC; Correia-Melo FS; Vieira F; Mello RP; Caliman-Fontes AT; Echegaray MVF; Marback RF; Guerreiro-Costa LNF; Souza-Marques B; Santos-Lima C; Souza LS; Bandeira ID; Kapczinski F; Lacerda ALT; Quarantini LC
Hum Psychopharmacol; 2022 Jul; 37(4):e2836. PubMed ID: 35179810
[TBL] [Abstract][Full Text] [Related]
38. Association between peripheral biomarkers and clinical response to IV ketamine for unipolar treatment-resistant depression: An open label study.
Kang MJY; Vazquez GH
J Affect Disord; 2022 Dec; 318():331-337. PubMed ID: 36070831
[TBL] [Abstract][Full Text] [Related]
39. [Ketamine's antidepressant effect: focus on ketamine mechanisms of action].
De Maricourt P; Jay T; Goncalvès P; Lôo H; Gaillard R
Encephale; 2014 Feb; 40(1):48-55. PubMed ID: 24434007
[TBL] [Abstract][Full Text] [Related]
40. [Ketamine in antidepressant treatment: a revolution?].
Fossati P
Biol Aujourdhui; 2023; 217(3-4):151-154. PubMed ID: 38018942
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
